Sionna Therapeutics (NASDAQ:SION) Director Sells 85,918 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 85,918 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. The trade was a 3.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Tuesday, June 30th, Orbimed Advisors Llc sold 115,844 shares of Sionna Therapeutics stock. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00.
• On Wednesday, May 27th, Orbimed Advisors Llc sold 101 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total value of $4,493.49.
• On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58.
• On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total value of $2,664,412.86.
• On Thursday, May 7th, Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.61, for a total transaction of $2,165,637.06.
• On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96.
• On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.68, for a total transaction of $2,341,097.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total value of $2,128,201.14.

Sionna Therapeutics Trading Up 2.1%

Shares of Sionna Therapeutics stock traded up $0.94 during trading hours on Thursday, reaching $44.94. 697,997 shares of the company’s stock were exchanged, compared to its average volume of 369,839. Sionna Therapeutics, Inc. has a 52-week low of $16.38 and a 52-week high of $48.44. The company has a fifty day moving average of $40.18 and a 200-day moving average of $39.52. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -23.28 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, equities research analysts anticipate that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Institutional Trading of Sionna Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its holdings in Sionna Therapeutics by 16.8% in the 1st quarter. Bank of America Corp DE now owns 50,870 shares of the company’s stock valued at $2,039,000 after purchasing an additional 7,303 shares in the last quarter. Stempoint Capital LP purchased a new position in Sionna Therapeutics in the first quarter valued at about $1,465,000. Walleye Capital LLC acquired a new position in shares of Sionna Therapeutics during the first quarter worth about $605,000. AlphaCentric Advisors LLC boosted its position in shares of Sionna Therapeutics by 77.1% in the first quarter. AlphaCentric Advisors LLC now owns 4,818 shares of the company’s stock worth $193,000 after buying an additional 2,098 shares during the period. Finally, Jennison Associates LLC grew its stake in shares of Sionna Therapeutics by 30.1% in the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after buying an additional 335,942 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SION. BTIG Research reiterated a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. JonesTrading upped their price target on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Wedbush assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price target on the stock. Finally, Wall Street Zen lowered shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $53.22.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.